News
Boehringer partners with UK’s Autifony for CNS therapeutics
UK-based biotechnology firm Autifony Therapeutics has entered an agreement with Boehringer Ingelheim regarding select aspects of its Kv3.1/3.2 voltage-gated potassium channel modulator platform. In line with Boehringer’s drug discovery strategy for neuropsychiatric diseases, the collaboration […]